Financial PerformanceAptar Pharma is the most profitable unit in AptarGroup, contributing to 40% of sales and 65% of EBITDA in 2022.
Growth PotentialAptarGroup's Pharma segment saw a 13% increase in organic growth in Q1, driven by strong demand for proprietary drug delivery systems and injectables.
Strategic PositioningAptarGroup is well positioned to deliver long-term compounding value through organic growth, acquisitions, and dividends.